Concepedia

Author

Maria Orr

AstraZeneca (United Kingdom)

Also Known As

M C M Orr, M Orr, M. Orr, Maria C M Orr, Maria C. M. Orr, Maria C.M. Orr, Maria Orr

27

Publications

2.4K

Citations

13

H-Index

17

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)University College LondonCRUK Lung Cancer Centre of ExcellenceEdinburgh Cancer Research
MO

About

Maria Orr is an author at AstraZeneca (United Kingdom) specializing in medicine, cancer therapeutics, and obstetrics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

1.5K

2

Obstetrics

3

3

1.5K

3

Pathology

2

2

58

4

Natural Sciences

1

1

52

5

Molecular Biology

1

1

52

Maria Orr

×

13

Publications

2.3K

Citations

12

H-Index

YearCitations

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Jonathan A. Ledermann, Philipp Harter, Charlie Gourley,

The Lancet Oncology

2014

1.4K

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Darren Hodgson, Brian Dougherty, Zhongwu Lai,

British Journal of Cancer

2018

225

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

Gillian Ellison, Emma Donald, Gael McWalter,

Journal of Experimental & Clinical Cancer Research

2010

152

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

Ruth Board, Gillian Ellison, Maria Orr,

British Journal of Cancer

2009

100

Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

Brian Dougherty, Zhongwu Lai, Darren Hodgson,

Oncotarget

2017

92

Targeted therapies in colorectal cancer—an integrative view by PPPM

Suzanne Hagan, Maria Orr, Brendan Doyle

The EPMA Journal

2013

84

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Pasi A. Jänne, Ian C. P. Smith, Gael McWalter,

British Journal of Cancer

2015

74

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Kyaw Lwin Aung, Emma Donald, Gillian Ellison,

Journal of Molecular Diagnostics

2014

52

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).

Jonathan A. Ledermann, Philipp Harter, Charlie Gourley,

Journal of Clinical Oncology

2013

39

435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Darren Hodgson, Brian Dougherty, Zefeng Lai,

European Journal of Cancer

2015

25

Page 1